Coya Announces Acceptance Of Oral Presentation, "Regulatory T Cell Expansion Strategy To Target Inflammation In Alzheimer's Disease: A Phase 1 Feasibility Study," At The 18th International Conference On Alzheimer's And Parkinson's Disease In Lisbon
Portfolio Pulse from Benzinga Newsdesk
Coya announced that data from a proof-of-concept study on Alzheimer's Disease (AD) patients treated with Low Dose IL-2 (LD IL-2) will be presented at the 18th International Conference on Alzheimer's and Parkinson's Disease. The study showed significant improvement in cognitive function. A double-blind, placebo-controlled study funded by the Gates Foundation and Alzheimer's Association is fully enrolled and will release data in 2024. Coya's proprietary LD IL-2 (COYA 301) is being developed as a treatment for AD.
October 27, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coya's announcement of positive preliminary results from its Alzheimer's treatment study and the upcoming presentation at an international conference could boost investor confidence in the short term.
The announcement of positive preliminary results from a study on Coya's Alzheimer's treatment, along with the upcoming presentation at an international conference, could be seen as a positive development by investors. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100